Cooperative Agreement 2151522

Award Date 3/1/22
Completion Date 2/28/25
Dollars Obligated $1M
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Buffalo, NY 14214, USA
Similar Awards
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $343,203 to Cyion Technologies LLC to develop a novel in vitro electrophysiology system for high-throughput measurement of intracellular action potential (IAP) in human-derived cardiomyocytes. The system leverages a 3D nanoelectrode array (NEA) technology to enable scalable recordings of IAP signals from many individual cardiomyocytes. This...
This SBIR Phase I project awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) will enable the generation of a massive dataset of small molecule and protein interactions to accelerate drug discovery using machine learning. The $275,000 award to Om Therapeutics Inc. aims to develop the capability to identify interactions between billions of unique small molecules and the entire human proteome. The innovation could...
This $599,486 National Science Foundation award under the Engineering (47.041) program will fund the development of an engineered cardiac tissue model with embedded soft microelectronics for continuous cardiotoxicity screening at The Pennsylvania State University from January 2022 to September 2023. The key product is a 3D-bioprinted, microvascularized cardiac tissue model integrated with stretchable microelectronics to enable real-time, intra-tissue measurement of cardiotoxicity responses to...
This $274,990 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships) supports the development of a physics-based machine learning platform for predicting the crystal structure of small drug molecules. The technology aims to accelerate and reduce the cost of early-stage pharmaceutical research and development by computationally analyzing the crystal structure properties that determine key...
The National Science Foundation awarded Cardiophi LLC $532,000 under the Technology, Innovation, and Partnerships program to develop an artificial intelligence solution for the automated interpretation of electrocardiograms. The project aims to refine existing deep learning-based algorithms for detecting irregular heartbeats, develop methods for predicting the onset of cardiac arrhythmias, and create interpretable and explainable tools to provide insights from ECG signals to clinicians....
The National Science Foundation (NSF) awarded a $275,000 Phase I Small Business Innovation Research (SBIR) grant under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program to KAI TECH LLC. The funding supports the development of an advanced software system called ECG-AID for automated electrocardiogram (ECG) analysis and interpretation. The ECG-AID prototype integrates a comprehensive ECG database, Z-score-based assessments, and machine-learning techniques to enhance the...
RCE Technologies, Inc. was awarded a $255,892 Small Business Innovation Research Phase I Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program to develop a proof-of-concept machine learning-based diagnostic system for detecting myocardial infarction and ischemia in real-time. The system aims to provide point-of-care clinical classification for heart attack cases using a novel, portable device integrating the awardee's proprietary external...
This National Science Foundation (NSF) Small Business Technology Transfer (STTR) Phase I award provides $275,000 to Neuraltrak, Inc. to develop and validate a method for continuous, real-time cardiac rhythm diagnosis and display using high-quality atrial electrogram data. The project aims to address limitations of current post-operative cardiac rhythm monitoring approaches, which often fail to accurately interpret rhythm due to poor atrial signal quality and patient variability. The...
This Project Grant award from the National Science Foundation (NSF) under the Engineering program (CFDA 47.041) provides $199,992 to Boston University to develop a high-throughput electrical stimulation screening platform for assessing the long-term effects of cardiac contractility modulation (CCM) devices on engineered human heart tissue. The project will support a postdoctoral scholar co-mentored by researchers at the Food and Drug Administration (FDA) and Boston University to advance...
This $275,000 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development and validation of an automated method for continuous post-operative cardiac rhythm diagnosis. The project, led by Atrility Medical, Inc., aims to improve the accuracy and accessibility of post-operative rhythm monitoring through the use of high-quality atrial electrogram signals. The anticipated outcome is a real-time, continuous...

SBIR PHASE II: DEVELOPING A PLATFORM FOR SUPERIOR PREDICTIVE ANALYSIS OF HERG ION CHANNEL-DRUG INTERACTIONS FOR THE COMPREHENSIVE IN-VITRO PROARRHYTHMIA ASSAY (CIPA) -THE BROADER IMPACT /COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT IS TO IMPROVE DRUG SAFETY. THIS PROJECT ADVANCES SOFTWARE TO IDENTIFY THE POTENTIAL OF NEW DRUGS TO PROVOKE DANGEROUS CARDIAC SIDE-EFFECTS. BECAUSE SUDDEN CARDIAC DEATH IS AN INFREQUENT AND RELATIVELY RARE PHENOMENON, PREDICTING IT WITH CONVENTIONAL TOOLS IS EITHER IMPRACTICAL OR IMPOSSIBLE. THE PROPOSED TECHNOLOGY WILL MAKE THE DEVELOPMENT OF ALL NEW CLASSES OF DRUGS SAFER, FASTER, AND LESS EXPENSIVE. THIS WILL BE INTEGRATED INTO INVESTIGATIONAL NEW DRUG SUBMISSION PACKAGES FOR SUBMISSION TO THE FDA FOR DRUG APPROVAL. THIS WILL IMPROVE PHARMACEUTICAL SAFETY AND CLINICAL OUTCOMES. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROJECT WILL ADDRESS THE CRITICAL PROBLEM OF PREDICTING THE ARRHYTHMOGENIC POTENTIAL OF NEW DRUGS SEEKING FDA APPROVAL. CURRENT BASIC SCIENCE RESEARCH METHODS ARE BASED ON TRYING TO REPRODUCE EXACT AND INFREQUENTLY ENCOUNTERED IN VIVO PHENOMENA IN AN IN VITRO SETTING. THE ECONOMIC AND PRACTICAL CONSTRAINTS ON DRUG DEVELOPMENT THEREFORE REQUIRES INDUSTRY TO USE PROXIES, PRIMARILY DRUG BINDING TO THE HERG POTASSIUM CHANNEL, AS A PREDICTOR ARRHYTHMOGENICITY. THE INTELLECTUAL CHALLENGE IN THIS PROJECT IS TO COMBINE MATHEMATICAL MODELING AND QUANTITATIVE ANALYSIS OF RIGOROUS EXPERIMENTAL PROTOCOLS TO BRIDGE THIS GAP AND IDENTIFY UNDERLYING FEATURES WHICH ARE STRONG PREDICTORS OF ARRHYTHMOGENIC BEHAVIOR. KEY TO UNDERSTANDING THIS IS THE RAPID DEVELOPMENT AND DEPLOYMENT OF STATE-DEPENDENT MARKOV MODELS OF DRUG ACTION BASED ON LIMITED PATCH CLAMP DATA, WHICH IS BOTH TIME-CONSUMING AND EXPENSIVE TO OBTAIN. THIS PROJECT COMBINES MATHEMATICAL ANALYSIS DIRECTLY TO DIRECT PATCH-CLAMP ASSAY PROTOCOLS TO MINIMIZE TIME AND EXPENSE WHILE INCREASING PREDICTIVE ACCURACY. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

Posted 2/24/22, 12:00 AM